INO Health & Biotech Stock Guide
Preview Issue #11 - February 28, 2017
BIOTECH, HEALTH & PHARMA NEWS
Johnson & Johnson and McKesson make a big splash in merger and acquisition activity, courts block Humana/Aetna merger and Allergan and Endo sued by FTC. The healthcare cohort has witnessed several key events in the face of a political backdrop that’s put the entire industry on edge. The overall healthcare umbrella has become sensitive to any tweet from President Trump as he vows to bring down drug prices. As he pursues his crusade against drug pricing, much of these threats may have already been priced-in as seen in many healthcare-related stocks (i.e. McKesson, CVS, ABBV and AGN) that have seen sharp and sustained sell-offs that coincide with the 2017 presidential campaign cycle.
Continue reading "Preview Issue #11: J&J $30B Acquisition, Humana/Aetna Blocked and Allergan Sued"
Hello MarketClub members everywhere. Stocks are fluctuating near all-time highs as investors weigh the prospects for further gains after mixed corporate earnings from companies including Netflix Inc. (NASDAQ:NFLX), Johnson & Johnson (NYSE:JNJ) and The Goldman Sachs Group Inc.(NYSE:GS).
Key levels to watch this week: Continue reading "Stocks Take A Breather"
There's a good reason that investors love high yielding dividend stocks. Not only does a dividend help buffer against downside risk, it also provides a steady base of returns over time that compounded, can add up to higher growth than you might expect.
Usually investors think of dividend paying stocks as large behemoths that simply don't have the ability to grow like it's smaller, younger competitors. It's a myth that's led many investors away from solid opportunities. These large entities might grow at a slower rate than you want, but when you factor in the dividends and the small downside risk these companies tend to have, you could find an investment that matches any high-risk small cap growth stock without having to expose yourself to unnecessary risk.
For a good example, all we need to do is look at Johnson & Johnson's (JNJ) stock.
Chart courtesy of StockCharts.com
If you bought 100 shares 10 years ago and reinvested all dividends, your holdings would have grown nearly 140%. And if you take a look at it's performance over that time, you'll see it's a very low-risk stock that was easily able to weather the 2008 financial crisis essentially making it a growth stock without the high growth risk. Continue reading "This High-Yield Stock Will Ensure Steady Profits In Your Portfolio"
As America ages, healthcare is going to be an important issue. How companies approach this is going to make a big difference to their bottom line.
The new Affordable Care Act, which is slowly being implemented, is another dimension that will have to be factored into the future. How companies adapt and make money in the future may have more to do with how they do business, rather than the drugs they are pushing.
Today, I'll be looking at four stocks, two that are in strong bullish trends according to the Trade Triangle technology, and two that are in downtrends.
From the long side based on the Trade Triangle technology:
Abbott Laboratories (NYSE:ABT)
Johnson & Johnson (NYSE:JNJ)
From the short side based on the Trade Triangle technology:
Amgen Inc. (NASDAQ:AMGN)
Pfizer, Inc. (NYSE:PFE)
Every success with MarketClub,
Adam appears frequently on the following financial news channels as a guest expert. Click on any cable logo to watch Adam's latest appearance.